甘精胰岛素联合芪药消渴胶囊治疗2型糖尿病的临床研究及安全性分析  

Clinical Study and Safety Analysis of Insulin Glargine Combined with Qiyao Xiaoke Capsule in the Treatment of Type 2 Diabetes

作　　者：蔡志敏 CAI Zhimin(Shenzhen Hospital of Beijing University of Chinese Medicine(Longgang)Traditional Chinese Medicine Internal Medicine,Shenzhen,Guangdong Province,518100 China)

机构地区：[1]北京中医药大学深圳医院(龙岗)中医内科学,广东深圳518100

出　　处：《系统医学》2021年第12期27-30,64,共5页Systems Medicine

摘　　要：目的探讨甘精胰岛素联合芪药消渴胶囊治疗2型糖尿病的疗效及安全性。方法选择该院消化内科从2018年1月—2019年11月期间收治的2型糖尿病患者86例随机分为联合治疗组和对照组,两组患者均接受降糖及降血脂的常规治疗,对照组患者在此基础上接受甘精胰岛素治疗,联合治疗组患者在对照组基础上接受芪药消渴胶囊治疗。比较两组患者治疗前及治疗4周后FPG、2 hPG、HbAlc、TC、HDL-C、LDL-C及TG水平;比较两组患者治疗前及治疗4周后SOD、MDA及AOPPs水平;比较两组患者治疗4周后的不良反应。结果治疗后联合治疗组FPG为(5.71±0.34)mmol/L、2 hPG为(7.21±1.03)mmol/L、HbAlc为(7.16±0.77)%,对照组FPG为(6.30±0.56)mmol/L、2 hPG为(8.06±1.43)mmol/L、HbAlc为(7.89±0.92)%,治疗4周后,联合治疗组患者FPG、2 hPG及HbAlc水平均低于对照组患者,差异有统计学意义(t=5.905、3.163、3.990,P<0.05);治疗后联合治疗组TC为(3.66±0.59)mmol/L、HDL-C为(1.54±0.32)mmol/L、LDL-C为(2.07±0.33)mmol/L、TG为(1.50±0.22)mmol/L,对照组TC为(4.27±0.64)mmol/L、HDL-C为(1.36±0.31)mmol/L、LDL-C为(2.32±0.32)mmol/L、TG为(1.73±0.28)mmol/L,联合治疗组患者TC、LDL-C及TG水平均低于对照组患者,差异有统计学意义(t=4.595、3.566、4.235,P<0.05),HDL-C水平高于对照组患者,差异有统计学意义(t=2.645,P<0.05);治疗后联合治疗组SOD为(40.98±3.37)IU/mL,MDA为(4.21±1.50)nmol/mL,AOPPs为(45.63±8.97)μg/L,对照组SOD为(35.41±4.34)IU/mL,MDA为(6.10±1.38)nmol/mL,AOPPs为(55.31±10.26)μg/L,联合治疗组患者MDA及AOPPs水平均低于对照组患者,差异有统计学意义(t=6.081、4.660,P<0.05),SOD水平高于对照组患者,差异有统计学意义(t=6.647,P<0.05);两组患者不良反应发生率相比较差异无统计学意义(P>0.05)。结论甘精胰岛素联合芪药消渴胶囊治疗2型糖尿病的效果确切,能够明显调节患者糖脂代谢水平,控制血糖及血脂,减轻患者氧化应激反应,且不Objective To investigate the efficacy and safety of insulin glargine combined with Qiyao Xiaoke Capsule in the treatment of type 2 diabetes.Methods A total of 86 patients with type 2 diabetes who were admitted to the Department of Gastroenterology in the hospital from January 2018 to November 2019 were randomly divided into a combination treatment group and a control group.Both groups received conventional treatment for blood glucose and blood lipid reduction.Patients in the control group received insulin glargine treatment on this basis,and patients in the combination treatment group received Qiyao Xiaoke capsule treatment on the basis of the control group.Compare the levels of FPG,2 hPG,HbAlc,TC,HDL-C,LDL-C and TG before treatment and 4 weeks after treatment between the two groups;compare the levels of SOD,MDA and AOPPs before treatment and 4 weeks after treatment between the two groups;compare the adverse reactions of patients in the two groups after 4 weeks of treatment.Results After treatment,the FPG of the combined treatment group was(5.71±0.34)mmol/L,2 hPG was(7.21±1.03)mmol/L,HbAlc was(7.16±0.77)%,the control group FPG was(6.30±0.56)mmol/L,and 2 hPG was(8.06±1.43)mmol/L and HbAlc were(7.89±0.92)%.After 4 weeks of treatment,the levels of FPG,2 hPG and HbAlc in the combined treatment group were lower than those in the control group,the difference was statistically significant(t=5.905,3.163,3.990,P<0.05).After treatment,the TC of the combined treatment group was(3.66±0.59)mmol/L,HDL-C was(1.54±0.32)mmol/L,LDL-C was(2.07±0.33)mmol/L,TG was(1.50±0.22)mmol/L,and the control group TC was(4.27±0.64)mmol/L,HDL-C was(1.36±0.31)mmol/L,LDL-C was(2.32±0.32)mmol/L,TG was(1.73±0.28)mmol/L,TC,LDL-C and TG in the combined treatment group were lower than those in the control group,the difference was statistically significant(t=4.595,3.566,4.235,P<0.05),and the level of HDL-C was higher than those in the control group,the difference was statistically significant(t=2.645,P<0.05);SOD in the combined treatment gr

关 键 词：甘精胰岛素 芪药消渴胶囊 2型糖尿病 糖脂代谢 氧化应激反应 

分 类 号：R59[医药卫生—内科学]